Characteristics of the studies using beta-blockers in patients with chronic obstructive pulmonary disease (COPD) and cardiovascular comorbidities

First author [ref.]YearDesignPopulationSafety outcome
Salpeter [15]2005Review of data from 22 randomised, blinded controlled trials1567 patients with COPDNo adverse effect of cardioselective beta-blockers on lung function or respiratory symptoms compared to placebo
Short [16]2011Retrospective cohort study using a disease-specific database of COPD patients (TARDIS)5977 patients aged >50 years with COPDReductions in mortality, exacerbations and hospital admissions; additive benefits with inhaled therapy; 88% of beta-blockers used were cardioselective
Etminan [14]2012Systematic review and meta-analysis of nine retrospective cohort studies99 877 patients with COPDProtective effect of beta-blockers (selective and non-selective) with respect to all-cause mortality
Stefan [2]2012Retrospective cohort study35 082 patients aged >40 years with COPD and coexistent ischaemic heart disease, chronic heart failure or hypertensionβ1-selective beta-blocker therapy among chronic users appears to be safe during a hospitalisation for acute COPD exacerbation; β1-selective beta-blockers are superior to non-selective beta-blockers in this category of patients
Zeng [17]2013Retrospective cohort study220 elderly male COPD patients (mean±sd age 84.1±6.9 years)No association between the use of β2-agonists, beta-blockers or beta-blocker/β2-agonist combination therapy with cardiac function and all-cause mortality in elderly male COPD patients

TARDIS: Tayside Allergy and Respiratory Disease Information System.